Spring 2024 funding cycle: Applications closed, funding results available before end of May 2024
Fall 2024 funding cycle:
- Call opens: Thursday, August 29, 2024
- Deadline: Monday September 30, 2024 (2:00 pm PST)
- Funding results: available before end of December, 2024
Amount available: $50,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The CFAR Mentored Scientist Award (our primary award program) is a mentoring and training grant targeted toward early stage (either at a senior stage of clinical or postdoctoral training or junior faculty) investigators at UCSF or affiliated partner institutes in the conduct of an HIV research project. These awards are designed to acquire preliminary data and research skills to prepare investigators for a future grant effort. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project.
Designation of Mentor
All Mentored award applications from individuals at the Assistant Professor level or below require an HIV research mentor. Mentors can, but are not required to, have supervisory authority over the applicant. CFAR requires your research mentor’s support to advise and guide the research portion of your application before submitting it to RAP.
Of high interest to CFAR are investigations ranging from basic pathogenesis to clinical outcomes in the research areas of HIV/aging and inflammation, latency, cure, vaccines, co-infections, HIV in women, implementation science, and research related to health disparities in HIV-infected and HIV-impacted Bay Area populations. Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $50,000 in direct costs for one year.
For more detailed information about this RFA, please see the RAP Portal.
To see examples of previously funded projects, see the list below.
Mentored Science Awardees
123 Awards
-
“Our Lives Matter”: Exploring the Impact of COVID-19 on Black/African American and Latino Sexual Minority Men Access to HIV Prevention and Treatment Services, Resource Security, and Vaccination Acceptance and Uptake
“Our Lives Matter”: Exploring the Impact of COVID-19 on Black/African American and Latino Sexual Minority Men Access to HIV Prevention and Treatment Services, Resource Security, and Vaccination Acceptance and Uptake
Abstract
There is an urgent convergence of two pandemics that is disproportionately affecting marginalized racial (Black/African American and Latino) and sexual minority men, HIV and SARS-CoV-2 (COVID-19). The current COVID-19 pandemic has disrupted HIV treatment and prevention services, with the full impact of that disruption still unknown. Additionally, as the race for a safe and effective vaccine against COVID-19 continues, there is growing skepticism and fear regarding their safety and effectiveness.
-
Urogenital and rectal Mycoplasma genitalium in men who have sex with men and transgender women at high risk for STIs: a pilot study of prevalence and antibiotic resistance
Urogenital and rectal Mycoplasma genitalium in men who have sex with men and transgender women at high risk for STIs: a pilot study of prevalence and antibiotic resistance
Abstract
Mycoplasma genitalium is an under-recognized but important contributor to the STI epidemic in the United States. Bacterial STIs are concentrated among men who have sex with men (MSM), and disproportionately affect those living with HIV or on PrEP. Studies outside of the U.S. have demonstrated a substantial burden of asymptomatic M. genitalium in MSM. U.S. data on asymptomatic M. genitalium prevalence are limited, with a single study of MSM living with HIV showing urogenital and rectal prevalence of 10.8% and 6.4%, respectively. M.
-
Application of quantitative intersectionality methods to identify the most vulnerable populations in the HIV continuum of care
Application of quantitative intersectionality methods to identify the most vulnerable populations in the HIV continuum of care
Abstract
People with severe mental illness (e.g., schizophrenia, bipolar disorder; SMI) are a socially marginalized population with up to ten times increased likelihood of being diagnosed with HIV compared to the general US population. The parent grant (R01-MH112420) aims to investigate the increased HIV transmission risk, low testing rate, and potential HIV treatment gaps for people with SMI using a large, geographically diverse national retrospective longitudinal Medicaid cohort.
-
Addressing Health Disparities Among Transgender Women in the Middle East
Addressing Health Disparities Among Transgender Women in the Middle East
Abstract
HIV risk and mental health morbidity are high among transgender women in Lebanon. We culturally adapted and pilot-tested an existing intervention in the Lebanese context. ‘Baynetna’ (Arabic for “between us” and a play on the word for “girls”) shows great promise to impact HIV risk and mental health through the model of Gender Affirmation for increasing community connectedness via trans-facilitated small group support.
-
Weight gain and metabolic consequences of switch to dolutegravir in Western Kenya
Weight gain and metabolic consequences of switch to dolutegravir in Western Kenya
Abstract
Dolutegravir was recently recommended as a component of first-line antiretroviral therapy (ART) for all adults living with HIV by the World Health Organization due to improved efficacy and tolerability over prior regimens. However, recent studies, including two randomized trials in sub-Saharan Africa, have shown significant weight gain associated with dolutegravir among ART-naïve patients newly initiating dolutegravir. It is not known whether switch to dolutegravir among ART-experienced patients will result in similar weight gain.
-
Potent Anti-HIV Gene Editing in Primary Myeloid Cells using CRISPR-Cas9 Technology
Potent Anti-HIV Gene Editing in Primary Myeloid Cells using CRISPR-Cas9 Technology
Abstract
Although HIV eradication efforts have mainly focused on latently-infected CD4+ T cells, myeloid cells harbor virus during suppressive antiretroviral therapy and participate in HIV dissemination and persistence. Infection of monocytes and macrophages contributes to inflammation and HIV-associated neurocognitive disorder (HAND). CRISPR/Cas9-mediated anti-HIV gene editing has been applied to excise HIV provirus and knock out the CXCR4 and CCR5 HIV co-receptors in CD4+ T cells as a cure approach. However, anti-HIV gene editing in the myeloid compartment has not been reported as yet. -
Racial/Ethnic Disparities for HIV-related Risks and Health Outcomes among Black Trans Women in the African Diaspora
Racial/Ethnic Disparities for HIV-related Risks and Health Outcomes among Black Trans Women in the African Diaspora
Abstract
Trans women bear a disproportionate burden of HIV worldwide. Within this population, Black trans women face a disparity within this disparity, with higher prevalence of HIV and worse clinical outcomes. The extraordinarily high burden of HIV among Black trans women merits urgent investigation. This study proposes to investigate racial/ethnic disparities in the population most severely affected by HIV worldwide – Black trans women, with inclusion of African-Americans and Afro-Brazilians as part of the wider African diaspora.
-
Assessing CSF HIV antibodies and CNS HIV viral reservoirs in HIV-Associated Neurocognitive Disorder (HAND)
Assessing CSF HIV antibodies and CNS HIV viral reservoirs in HIV-Associated Neurocognitive Disorder (HAND)
Abstract
Levels of cerebrospinal fluid (CSF) HIV antibodies are theorized as a broad marker of central nervous system (CNS) HIV reservoir size. In the proposed work, I will determine CSF HIV antibody levels and their antigenic targets in virally suppressed HIV+ elders with (n=30) and without (n=15) HIV-associated neurocognitive disorder (HAND).
-
Surface engineering of exosomes to specifically bind and kill HIV-infected cells
Surface engineering of exosomes to specifically bind and kill HIV-infected cells
Abstract
The current limitations of antiretroviral therapy is driving interest in alternative therapeutics which fully resolve inflammation and achieve complete eradication of HIV latently-infected cells. Exosomes are nano-sized membrane vesicles and key players of intercellular signaling. Interestingly, exosomes have shown promise as engineerable therapeutic agents for a broad range of diseases. The objective of this grant is to surface engineer exosomes ex vivo using surface display technology and pack the decorated exosomes with cytotoxic cargo.
-
Linkages between gender-based violence and engagement in HIV care in a prospective cohort of U.S. women living with HIV
Linkages between gender-based violence and engagement in HIV care in a prospective cohort of U.S. women living with HIV
Abstract
Evidence is mounting that gender-based violence (GBV) is a major barrier to engagement in HIV care and treatment, and viral suppression. Research has documented the powerful role of GBV on ART uptake and adherence, including a meta-analysis showing that intimate partner violence had a larger effect on adherence than other factors such as stigma, financial constraints, and pill burden. Yet four key gaps in knowledge remain.